These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1894188)

  • 1. Clinical pharmacology of recombinant hirudin.
    Markwardt F; Nowak G; Stürzebecher J
    Haemostasis; 1991; 21 Suppl 1():133-6. PubMed ID: 1894188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinico-pharmacological studies with recombinant hirudin.
    Markwardt F; Nowak G; Stürzebecher J; Vogel G
    Thromb Res; 1988 Dec; 52(5):393-400. PubMed ID: 3222782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and anticoagulant effect of hirudin in man.
    Markwardt F; Nowak G; Stürzebecher J; Griessbach U; Walsmann P; Vogel G
    Thromb Haemost; 1984 Oct; 52(2):160-3. PubMed ID: 6523433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man.
    Bichler J; Siebeck M; Fichtl B; Fritz H
    Haemostasis; 1991; 21 Suppl 1():137-41. PubMed ID: 1716603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
    Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
    J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits.
    Kouz J; Czech J; Nicolay U; Dickneite G
    Haemostasis; 1996; 26(4):179-86. PubMed ID: 8872128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacology of recombinant hirudin, a new anticoagulant.
    Meyer BH; Luus HG; Müller FO; Badenhorst PN; Röthig HJ
    S Afr Med J; 1990 Sep; 78(5):268-70. PubMed ID: 2392724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration.
    Bichler J; Fichtl B; Siebeck M; Fritz H
    Arzneimittelforschung; 1988 May; 38(5):704-10. PubMed ID: 3415713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
    Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
    Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogs.
    Iyer L; Koza M; Iqbal O; Calabria R; Fareed J
    Thromb Res; 1993 Feb; 69(3):259-69. PubMed ID: 8475476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of recombinant hirudin in healthy horses.
    Feige K; Dennler M; Kästner SB; Wunderli-Allenspach H; Demuth D; Huber A
    Equine Vet J; 2004 Mar; 36(2):135-41. PubMed ID: 15038436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time.
    Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
    Haemostasis; 1996; 26(3):140-9. PubMed ID: 8738588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic studies with recombinant hirudin in dogs.
    Nowak G; Markwardt F; Fink E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):70-4. PubMed ID: 2459035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A recombinant hirudin (IK-HIR02) in healthy volunteers. II. Effects on platelet adhesion and platelet-induced thrombin generation time.
    Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
    Haemostasis; 1996; 26(4):187-94. PubMed ID: 8872129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure.
    Pöschel KA; Bucha E; Esslinger HU; Nörtersheuser P; Jansa U; Schindler S; Nowak G; Stein G
    Kidney Int; 2000 Dec; 58(6):2478-84. PubMed ID: 11115081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of r-hirudin in renal impairment.
    Nowak G; Bucha E; Gööck T; Thieler H; Markwardt F
    Thromb Res; 1992 Jun; 66(6):707-15. PubMed ID: 1519229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
    Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
    Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hirudin as anticoagulant in experimental hemodialysis.
    Markwardt F; Nowak G; Bucha E
    Haemostasis; 1991; 21 Suppl 1():149-55. PubMed ID: 1894190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
    Schiele F; Vuillemenot A; Kramarz P; Kieffer Y; Soria J; Soria C; Camez A; Mirshahi MC; Bassand JP
    Thromb Haemost; 1994 May; 71(5):558-62. PubMed ID: 8091380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental studies on a recombinant hirudin, CGP 39393.
    Gray E; Watton J; Cesmeli S; Barrowcliffe TW; Thomas DP
    Thromb Haemost; 1991 Apr; 65(4):355-9. PubMed ID: 2057916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.